Cancer-overexpressed nutrient transporters

Cancer-overexpressed nutrient transporters represent a broad class of membrane proteins, primarily from the solute carrier (SLC) family, that are significantly upregulated in malignant cells to meet the heightened metabolic demands of rapid proliferation [Ganapathy et al., 2009, nih.gov]. Key members include Glucose transporter type 1 (GLUT1), L-type amino acid transporter 1 (LAT1), Alanine/serine/cysteine-preferring transporter 2 (ASCT2), and Monocarboxylate transporter 1 (MCT1), which facilitate the influx of energy substrates and the efflux of metabolic waste like lactate [Ganapathy et al., 2009, nih.gov; Frontiers in Oncology, 2021]. This upregulation is a fundamental component of the Warburg effect, allowing tumors to maintain growth and survive within the nutrient-deprived and acidic tumor microenvironment [ScienceDaily, 2019; Frontiers in Oncology, 2021]. Therapeutically, these transporters are targeted using small-molecule inhibitors to induce metabolic starvation or are exploited as selective gateways for the delivery of cytotoxic prodrugs directly into cancer cells [Frontiers in Oncology, 2021; IIAR Journals, 2010]. For instance, inhibitors like JPH203 target LAT1 to block essential amino acid uptake, while drugs like AZD3965 inhibit MCT1 to disrupt lactate transport and cellular pH balance [ScienceDaily, 2019; Frontiers in Oncology, 2021]. However, the presence of these transporters in critical normal tissues, such as the blood-brain barrier and hematopoietic cells, poses a major challenge for achieving a wide therapeutic window and avoiding systemic toxicity [Frontiers in Oncology, 2021; News-Medical, 2026]. Despite these challenges, the differential expression of these transporters remains a promising area for developing personalized cancer therapies and diagnostic imaging tools [IIAR Journals, 2010].

Other names

Solute carrier transporters in cancerTumor-associated nutrient transportersMetabolic transportersNutrient permeases

Inhibition of nutrient uptake (e.g., glucose, amino acids) or metabolic byproduct efflux (e.g., lactate), leading to metabolic starvation, intracellular acidification, or induction of oxidative stress and ferroptosis [Ganapathy et al., 2009, nih.gov; Frontiers in Oncology, 2021].